Archives
- 2026-09
- 2026-08
- 2026-07
- 2026-06
- 2026-05
- 2026-04
- 2026-03
- 2026-02
- 2026-01
- 2025-12
- 2025-11
- 2025-10
- 2025-09
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
-
Angiotensin Peptides and SARS-CoV-2 Spike Binding
2026-08-18
Oliveira and colleagues showed that naturally occurring angiotensin fragments can increase SARS-CoV-2 spike-protein binding to host receptors, with especially strong effects in the spike–AXL interaction. The structure–activity findings extend renin-angiotensin system research into viral receptor biology while emphasizing that antibody-based binding results require validation in cellular and physiological models.
-
P2RX1 and Mitochondrial Apoptosis in Ph+ ALL
2026-08-18
Li et al. identify P2RX1 as a mechanistic link between calcium dysregulation, CaMKII activation, PI3K/Akt suppression, and mitochondrial apoptosis in Philadelphia chromosome-positive acute lymphoblastic leukemia. The findings suggest that P2RX1 may influence both disease behavior and tyrosine kinase inhibitor response, while also defining experimentally testable readouts for cell-death studies.
-
Capsaicin Workflows for TRPV1 and KDM1A Research
2026-08-17
Capsaicin enables a two-track research strategy: controlled TRPV1 ion channel activation in sensory models and mechanistic KDM1A/LSD1 inhibition in cancer studies. This workflow connects dose selection, electrophysiology, cell phenotyping, and troubleshooting while separating target-specific effects from solvent, desensitization, and cytotoxicity artifacts.
-
Olsalazine Sodium Experimental Workflows
2026-08-17
Olsalazine Sodium supports complementary workflows spanning LTB4-driven inflammation, colorectal cancer tumor models, and xenobiotic transport assays. This guide emphasizes aqueous formulation, paired molecular and functional readouts, and troubleshooting strategies that prevent solubility or interpretation errors.
-
Anlotinib Hydrochloride Angiogenesis Workflows
2026-08-16
Build more informative angiogenesis experiments with Anlotinib hydrochloride, a multi-target tyrosine kinase inhibitor that connects endothelial migration, tube formation, receptor phosphorylation, and ERK readouts. This workflow emphasizes dose selection, orthogonal validation, and troubleshooting so anti-angiogenic effects can be separated from nonspecific cytotoxicity.
-
Gramine Workflow for TNBC Ferroptosis Research
2026-08-15
Gramine is a practical chemical probe for connecting TNBC growth inhibition with ferroptosis, MTDH regulation, and CUL3-dependent ubiquitination. This workflow combines dose-response screening, orthogonal ferroptosis assays, target-engagement tests, and mechanistic rescue experiments for more reproducible cancer biology research.
-
Polybrene: Viral Delivery and p53 Assay Workflows
2026-08-14
Polybrene (Hexadimethrine Bromide) helps overcome charge-based barriers in viral gene delivery and difficult DNA transfections. This guide connects practical delivery optimization with mutant-p53 assay design, including controls, troubleshooting, and limits when studying p53Y220C reactivation.
-
Obeticholic Acid Workflows for Fibrosis Studies
2026-08-14
Obeticholic Acid provides a selective FXR-centered workflow for connecting bile acid regulation with cholestasis, inflammation, and fibrosis phenotypes. This guide combines hepatocyte assays, chronic liver injury models, reference-study insights, and troubleshooting strategies for more reproducible translational research.
-
α2-AR Activation in Osteosarcoma Recurrence
2026-08-13
A 2025 reference study identifies local delivery of the α2-adrenergic receptor agonist UK14,304 through a thermo-sensitive PLGA-PEG-PLGA hydrogel as a potential strategy for reducing post-surgical osteosarcoma recurrence. Its results support an immune-mediated mechanism involving CD8+ T-cell activity, T-cell receptor signaling, and ITGAL-centered tumor microenvironment changes rather than direct tumor-cell cytotoxicity.
-
Nirmatrelvir: From Protease Biology to Translation
2026-08-13
Nirmatrelvir (PF-07321332) offers translational researchers a mechanistically defined SARS-CoV-2 3CL protease inhibitor for connecting enzyme inhibition with cellular replication readouts, while clarifying the limits of docking-led antiviral discovery.
-
Vancomycin Hydrochloride in Resistance Assays
2026-08-12
Vancomycin hydrochloride can serve as more than a Gram-positive control: it helps researchers separate target-specific inhibition from exposure-dependent resistance behavior. This guide connects its D-alanyl-D-alanine mechanism with time-kill and PKPD principles from contemporary resistance research.
-
Saikosaponin D, Lactylation, and TNBC Radioresistance
2026-08-12
The reference study identifies MRE11 Lys673 lactylation as a lactate-sensitive DNA-repair mechanism that supports radiotherapy resistance in triple-negative breast cancer. It further shows that saikosaponin D activates the HIF1α/HDAC5 axis, promotes MRE11 de-lactylation, and improves radiation response, providing a mechanistic bridge between cancer metabolism and genome maintenance.
-
Docosahexaenoic Acid in Hippocampal Research
2026-08-11
Docosahexaenoic Acid (DHA) enables mechanistic neuroprotection research that connects lipid metabolism with synaptic structure, oxidative stress, apoptosis modulation, and cognitive outcomes. This workflow translates a rat postoperative cognitive dysfunction study into practical guidance for cell assays, spatial lipidomics, imaging, and intervention design.
-
Mianserin HCl: From Trial Signal to Assay Design
2026-08-11
Explore how Mianserin HCl links 5-HT2 receptor pharmacology, exposure measurement, formulation, and antipathogenic research. This evidence-led guide converts a landmark clinical study into practical assay decisions.
-
Fructus Rubi Glycosides in Benign Prostatic Hyperplasia
2026-08-10
The reference study identifies a diterpene glycoside extract from Fructus Rubi as a multitarget intervention for benign prostatic hyperplasia. By combining DARTS/MS target screening with DHT-responsive prostate cells and testosterone propionate-induced rats, the work connects androgen receptor signaling with the S100A2–TGF-β/Smad axis.